医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

FDA-registered FLEXpineBrace Is Now Available With Qualifying Healthcare Coverage

2021年10月04日 PM10:00
このエントリーをはてなブックマークに追加


 

SEONG-NAM CITY, South Korea

StandingTall, a maker of prescription-strength custom braces, recently registered with the FDA and is about to begin shipping its patented orthopedic back brace product, FLEXpineBrace.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211004005097/en/

FLEXpineBrace encourages proactive physical activity with maximum comfort (Photo: Business Wire)

FLEXpineBrace encourages proactive physical activity with maximum comfort (Photo: Business Wire)

Approved for the healthcare product billing code, patients enrolled in qualifying medical insurance programs can now save up to 80% of the cost of purchasing FLEXpineBrace at participating retail stores, hospitals, and clinics. Other commercially available prescription-grade braces are typically expensive and may result in a significant financial burden over time. StandingTall offers competitive pricing, which makes its product a truly affordable alternative.

From a design perspective, conventional braces use either all rigid or all band-type materials. They are too stiff to wear or soft for better back support. By contrast, FLEXpineBrace is an integrated assembly where each section uses a specific material to achieve optimal performance. For instance, the upper body frame is a medical-grade hard plastic, whereas the band component is elastic yet firm with flexibility for everyday comfort and fit. Notably, the band tightly wraps around the body’s curvature with pressure to gradually straighten a patient’s spinal or backbone curves. Since the hard-shell component does not cover the entire upper body, this allows the body waist to bend 150 degrees. Less recurrence of spinal/backbone curving over an extended period is also possible with regular back muscle strengthening exercises, even after removing the brace.

Unlike other braces on the market, FLEXpineBrace does not require visiting a medical office, wrapping the body with gauze, applying plaster bondage, and waiting until it dries. Instead, the X-Ray image and body measurement are the only information needed to develop a custom brace. Another advantage of using this product is that its modular construction requires only minor component adjustments to the height and weight change over time. Essentially, FLEXpineBrace is semi-permanent.

Last year, the company conducted a performance analysis with 300 participating patients who purchased the product. The astonishing result revealed an average of 40% improvement in the Thoracic Vertebrae and 37.5% improvement in the Lumbar Spine areas after six months of use. It represents a 20% higher yield rate of scoliosis correction, outperforming other braces in a similar category.

One of the surveyed patients was a 20-year-old woman with S-type scoliosis. The Cobb angle in her Thoracic Vertebrae was 39 degrees, and the Lumbar Spine was 40 degrees, with substantial differences in shoulder heights. After wearing FLEXpineBrace, not only did the shoulder level but the Cobb angle both in her Thoracic Vertebrae (31 degrees) and Lumbar Spine (16 degrees) have drastically improved.

Through FLEXpineBrace, StandingTall aims to improve the lives of many scoliosis patients. Currently, the company is actively seeking partners to achieve this common objective.

For additional details, please visit www.flexpine.com/en.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211004005097/en/

CONTACT

Sales and partnership inquiries:

Hyunhee Kwon

Business Development

(302) 313-1259

info@flexpine.com

同じカテゴリーの記事 

  • Rubedo Life Sciences和Beiersdorf宣布建立多年合作伙伴关系,共同开发解决细胞衰老问题的护肤新品
  • 日本天皇陛下和皇后出席2024年度日本奖颁奖典礼
  • Hyperfine, Inc. Takes the Stage at ISMRM with Seventeen Abstracts Assessing the Potential of Using Swoop® System Images Across Multiple Care Settings and Clinical Conditions
  • ReNAgade Therapeutics宣布在ASGCT第27届年会上发表演讲
  • ReNAgade TherapeuticsがASGCT第27回年次総会でのプレゼンテーションの内容を発表